Quantum Computing in drug discovery receives £6.85 million boost
Drug Discovery Today
NOVEMBER 9, 2021
Innovate UK grant awarded for the development of quantum computing in cancer treatment
Sat.Nov 06, 2021 - Fri.Nov 12, 2021
113 
New patent for Alkermes Inc drug ARISTADA INITIO KIT
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for ARISTADA+INITIO+KIT Aristada Initio Kit is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Alkermes Inc drug ARISTADA INITIO KIT appeared first on DrugPatentWatch - Make Better Decisions.
Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira
Drug Channels
NOVEMBER 9, 2021
The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release. Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough. Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar.
Leveraging Targeted Mouse I/O RNA-Seq Panels to Improve the Translatability of Immuno-Oncology Studies
Crown Bioscience
NOVEMBER 12, 2021
In this post, we explore how a targeted RNA-Sequencing (RNA-Seq) panel can be incorporated into preclinical drug development to evaluate the impact of immune effectors in mediating anti-tumor immunity of novel immuno-oncology (I/O) agents. A case study highlights how RNA-Seq panels can complement traditional protein-based assays to gain a truly comprehensive picture of novel immunotherapies.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
How to make the challenge of mRNA delivery easy
Tebu Bio: Drug Discovery
NOVEMBER 12, 2021
Many researchers are facing the challenges of mRNA delivery, through the body into the cytoplasm of cells. In this post, we invite you to discover some useful and efficient solutions to improve and control all the steps of your mRNA delivery project.
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 9, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities
The Pharma Data
NOVEMBER 11, 2021
Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy for chronic weight management in adults with obesity. Wegovy is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI?
Tips for Living with Plaque Psoriasis
Olympian Clinical Research
NOVEMBER 10, 2021
If you’ve been suffering from plaque psoriasis for a while, you may be frustrated and eager for something that can help. Living with plaque psoriasis can be difficult, and you might not know where to turn or who can help. Fortunately, there are tips and treatment options available to you to help lessen your symptoms. Symptoms of Plaque Psoriasis.
Which pharmaceutical companies have the most drug patents in Cyprus?
Drug Patent Watch
NOVEMBER 12, 2021
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Use of Social Media and Mobile Devices – Study Participants Recruitment
ProRelix Research
NOVEMBER 9, 2021
Use of Social Media and Mobile Devices – Study Participants Recruitment There has been a significant change in the clinical trial and advertising industries over the last five years that […]. The post Use of Social Media and Mobile Devices – Study Participants Recruitment appeared first on ProRelix Research.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
A target for potential cancer drugs may, in fact, worsen disease
The Pharma Data
NOVEMBER 10, 2021
In recent times, much scientific trouble and backing has concentrated on developing medicines that target an enzyme with the cumbrous name of Src homology 2- containing protein tyrosine phosphatase 2 or further briefly, Shp2. Shp2 is a phosphotyrosine phosphatase; its job is to remove phosphates from protein tyrosine remainders, abetting and abetting signal dispatches within cells.
New patent for Pfizer drug TALZENNA
Drug Patent Watch
NOVEMBER 12, 2021
Annual Drug Patent Expirations for TALZENNA Talzenna is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are five patents protecting…. The post New patent for Pfizer drug TALZENNA appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Gilead Sciences drug BIKTARVY
Drug Patent Watch
NOVEMBER 12, 2021
Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are ten…. The post New patent for Gilead Sciences drug BIKTARVY appeared first on DrugPatentWatch - Make Better Decisions.
New patent expiration for Bayer Hlthcare drug EOVIST
Drug Patent Watch
NOVEMBER 12, 2021
Annual Drug Patent Expirations for EOVIST Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent expiration for Bayer Hlthcare drug EOVIST appeared first on DrugPatentWatch - Make Better Decisions.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Which pharmaceutical drugs have the most drug patents in South Africa?
Drug Patent Watch
NOVEMBER 11, 2021
This chart shows the drugs with the most patents in South Africa. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in South Africa? appeared first on DrugPatentWatch - Make Better Decisions.
Which pharmaceutical companies have the most elixir dosed drugs?
Drug Patent Watch
NOVEMBER 10, 2021
This chart shows the pharmaceutical companies with the most elixir dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most elixir dosed drugs…. The post Which pharmaceutical companies have the most elixir dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Gilead Sciences drug VEMLIDY
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for VEMLIDY Vemlidy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are four…. The post New patent for Gilead Sciences drug VEMLIDY appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Eli Lilly drug VERZENIO
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for VERZENIO Verzenio is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There is…. The post New patent for Eli Lilly drug VERZENIO appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
New patent for Alnylam Pharms drug ONPATTRO
Drug Patent Watch
NOVEMBER 10, 2021
Annual Drug Patent Expirations for ONPATTRO Onpattro is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twenty-three patents protecting this drug. Drug patent…. The post New patent for Alnylam Pharms drug ONPATTRO appeared first on DrugPatentWatch - Make Better Decisions.
OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis
The Pharma Data
NOVEMBER 9, 2021
OLUMIANT ® (baricitinib) maintained a harmonious safety profile in a long- term, integrated safety analysis of cases with rheumatoid arthritis (RA) who entered OLUMIANT for patient times of exposure, in line with preliminarily published findings. Eli Lilly and Company (NYSE LLY) and Incyte (NASDAQ INCY) will present these results, along with real- world safety results from cases with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology’s virtual periodic meeting takin
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting
The Pharma Data
NOVEMBER 9, 2021
– More than 30 Abstracts Across HDV, HCV, HBV, NASH and PSC Reflect Gilead’s Ongoing Commitment to Addressing Challenges Facing People Living With Liver Diseases –. Gilead Lores,Inc. (Nasdaq GILD) moment blazoned the donation of new clinical and real- world data at the American Association for the Study of Liver Conditions (AASLD) The Liver Meeting ®, taking place from November 12-15.
Bayer grows sales and earnings significantly
The Pharma Data
NOVEMBER 9, 2021
Group sales rise by 14.3 percent (Fx & portfolio adj.) to 9.781 billion euros / EBITDA before special items increases by 16.4 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent to 1.05 euros / Net income at 85 million euros / Free cash flow remains strong at 1.954 billion euros / Revised outlook confirms good business performanc
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
The Pharma Data
NOVEMBER 9, 2021
Johnson & Johnson and its Janssen Pharmaceutical Companies moment blazoned they will appeal the$ 572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma’s action against opioid manufacturers. The Company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with civil and state laws, the unique part its drugs play in the lives of the people who need them, its responsible marketing practices and that
BIOHAVEN AND PFIZER ENTER STRATEGIC COLLABORATION FOR THE COMMERCIALIZATION OF RIMEGEPANT OUTSIDE THE UNITED STATES
The Pharma Data
NOVEMBER 9, 2021
Rimegepant, commercialized as Nurtec® ODT in the U.S., is the first and only oral CGRP (calcitonin gene- related peptide) receptor antagonist for the acute and preventive treatment of migraine Biohaven to receive tiered double-digit royalties on ex-U.S. net sales as well as upfront and milestone payments of up to $1.24 billion Biohaven and Pfizer global collaboration to be discussed on Biohaven 3Q Earnings Investor Call .
Study offers insights on why the elderly are more susceptible to COVID-19
The Pharma Data
NOVEMBER 9, 2021
Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma. In a new study published in the journal JCI Insight, Brown University researchers describe the cellular and molecular events that explain why these groups have a higher risk of infection as well as of severe side effects and death. “
New patent for Averitas drug QUTENZA
Drug Patent Watch
NOVEMBER 9, 2021
Annual Drug Patent Expirations for QUTENZA Qutenza is a drug marketed by Averitas and is included in one NDA. There are seven patents protecting this drug. Drug patent litigation for…. The post New patent for Averitas drug QUTENZA appeared first on DrugPatentWatch - Make Better Decisions.
New patent for Amarin Pharms drug VASCEPA
Drug Patent Watch
NOVEMBER 9, 2021
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-four patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.
First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia
The Pharma Data
NOVEMBER 8, 2021
Aimovig Demonstrated Superiority for Both the Primary and Secondary Endpoint Versus Topiramate Aimovig had a Significantly Lower Discontinuation Rate Due to Adverse Events Versus Topiramate More Patients in the Aimovig Treatment Arm Achieved at Least a 50 Percent Reduction in Monthly Migraine Days From Baseline Compared to Those in the Topiramate Treatment Arm.
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
The Pharma Data
NOVEMBER 8, 2021
Bristol Myers Squibb moment blazoned the Phase 3 CheckMate-816 trial met the primary endpoint of bettered event-free survival (EFS) in cases with resectable stage IB to IIIAnon-small cell lung cancer (NSCLC). In a prespecified interim analysis, Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful enhancement in EFS compared to chemotherapy alone when given before surgery.
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
The Pharma Data
NOVEMBER 8, 2021
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study / Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with finerenone reduced the risk of cardiovascular events and of disease progression of CKD, underpinning the imp
Which pharmaceutical companies have the most SPCs in Luxembourg?
Drug Patent Watch
NOVEMBER 8, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Luxembourg. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
New patent expiration for Sunovion drug BROVANA
Drug Patent Watch
NOVEMBER 8, 2021
Annual Drug Patent Expirations for BROVANA Brovana is a drug marketed by Sunovion and is included in one NDA. It is available from two suppliers. There are eleven patents protecting…. The post New patent expiration for Sunovion drug BROVANA appeared first on DrugPatentWatch - Make Better Decisions.
New patent expiration for Bayer Hlthcare drug GADAVIST
Drug Patent Watch
NOVEMBER 8, 2021
Annual Drug Patent Expirations for GADAVIST Gadavist is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent expiration for Bayer Hlthcare drug GADAVIST appeared first on DrugPatentWatch - Make Better Decisions.
Let's personalize your content